161 related articles for article (PubMed ID: 38756776)
1. Effectiveness of CAR-T treatment toward the potential risk of second malignancies.
Martino M; Porto G; Policastro G; Alati C; Loteta B; Micó MC; Argiró C; Altomonte M; Moscato T; Labate D; Dattola V; Rao CM; Cogliandro F; Canale FA; Naso V; Filippelli G; Iaria A; Pitea M
Front Immunol; 2024; 15():1384002. PubMed ID: 38756776
[No Abstract] [Full Text] [Related]
2. Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Pagel JM; West HJ
JAMA Oncol; 2017 Nov; 3(11):1595. PubMed ID: 28880983
[No Abstract] [Full Text] [Related]
3. CAR T-Cells and Safety Signals: ITT Episode 29.
N Engl J Med; 2024 Apr; 390(16):e39. PubMed ID: 38657243
[No Abstract] [Full Text] [Related]
4. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System.
Elsallab M; Ellithi M; Lunning MA; D'Angelo C; Ma J; Perales MA; Frigault M; Maus MV
Blood; 2024 May; 143(20):2099-2105. PubMed ID: 38483155
[TBL] [Abstract][Full Text] [Related]
5. CAR T Cell Therapy for Hematological Malignancies.
Yang X; Wang GX; Zhou JF
Curr Med Sci; 2019 Dec; 39(6):874-882. PubMed ID: 31845217
[TBL] [Abstract][Full Text] [Related]
6. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
7. Data mining for second malignancies after CAR-T.
Heslop HE
Blood; 2024 May; 143(20):2023-2024. PubMed ID: 38753361
[No Abstract] [Full Text] [Related]
8. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
10. CAR T-cells for relapsed B-cell ALL in adults.
Gilbert JA
Lancet Oncol; 2018 Mar; 19(3):e143. PubMed ID: 29429915
[No Abstract] [Full Text] [Related]
11. CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead.
Zhang Q; Ping J; Huang Z; Zhang X; Zhou J; Wang G; Liu S; Ma J
J Immunol Res; 2020; 2020():1924379. PubMed ID: 32411789
[TBL] [Abstract][Full Text] [Related]
12. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.
Ghassemi S; Milone MC
J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904011
[TBL] [Abstract][Full Text] [Related]
13. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
14. Expanding the role of CAR T-cell therapy: From B-cell hematological malignancies to autoimmune rheumatic diseases.
Shumnalieva R; Velikova T; Monov S
Int J Rheum Dis; 2024 May; 27(5):e15182. PubMed ID: 38742463
[TBL] [Abstract][Full Text] [Related]
15. CAR-T cell therapy and infection: a review.
Bupha-Intr O; Haeusler G; Chee L; Thursky K; Slavin M; Teh B
Expert Rev Anti Infect Ther; 2021 Jun; 19(6):749-758. PubMed ID: 33249873
[No Abstract] [Full Text] [Related]
16. Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy.
Zhu L; Yang X; Zhong D; Xie S; Shi W; Li Y; Hou X; HuaYao ; Zhou H; Zhao M; Ding Z; Zhao X; Mo F; Yin S; Liu A; Lu X
J Immunol Res; 2020; 2020():2454907. PubMed ID: 32964055
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
18. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory.
Thibodeaux SR; Milone MC
Clin Chem; 2019 Apr; 65(4):519-529. PubMed ID: 30593467
[TBL] [Abstract][Full Text] [Related]
20. Target selection for CAR-T therapy.
Wei J; Han X; Bo J; Han W
J Hematol Oncol; 2019 Jun; 12(1):62. PubMed ID: 31221182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
